| Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ... The Lancet Oncology 21 (11), 1413-1422, 2020 | 707 | 2020 |
| Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial) M Provencio, R Serna-Blasco, E Nadal, A Insa, MR García-Campelo, ... Journal of Clinical Oncology 40 (25), 2924-2933, 2022 | 233 | 2022 |
| Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer M Provencio, E Nadal, JL González-Larriba, A Martínez-Martí, R Bernabé, ... New England Journal of Medicine 389 (6), 504-513, 2023 | 218 | 2023 |
| Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition A Cruz-Bermúdez, R Laza-Briviesca, RJ Vicente-Blanco, ... Free Radical Biology and Medicine 135, 167-181, 2019 | 138 | 2019 |
| Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling A Cruz-Bermúdez, R Laza-Briviesca, RJ Vicente-Blanco, ... Free Radical Biology and Medicine 130, 163-173, 2019 | 114 | 2019 |
| Enhanced tumorigenicity by mitochondrial DNA mild mutations A Cruz-Bermúdez, CG Vallejo, RJ Vicente-Blanco, ME Gallardo, ... Oncotarget 6 (15), 13628, 2015 | 70 | 2015 |
| Nivolumab+ chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from … M Provencio-Pulla, E Nadal, JLG Larriba, A Martinez-Marti, R Bernabé, ... Journal of Clinical Oncology 40 (16_suppl), 8501-8501, 2022 | 65 | 2022 |
| hCOA3 stabilizes cytochrome c oxidase 1 (COX1) and promotes cytochrome c oxidase assembly in human mitochondria P Clemente, S Peralta, A Cruz-Bermudez, L Echevarría, F Fontanesi, ... Journal of Biological Chemistry 288 (12), 8321-8331, 2013 | 56 | 2013 |
| Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy M Provencio, V Calvo, A Romero, JD Spicer, A Cruz-Bermúdez American Society of Clinical Oncology Educational Book 42, 711-728, 2022 | 50 | 2022 |
| Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial R Laza‐Briviesca, A Cruz‐Bermúdez, E Nadal, A Insa, ... Clinical and Translational Medicine 11 (7), e491, 2021 | 47 | 2021 |
| Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy M Casarrubios, A Cruz-Bermúdez, E Nadal, A Insa, MR García Campelo, ... Clinical Cancer Research 27 (21), 5878-5890, 2021 | 45 | 2021 |
| Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant … M Casarrubios, M Provencio, E Nadal, A Insa, ... Journal for immunotherapy of cancer 10 (9), 2022 | 35 | 2022 |
| Functional characterization of three concomitant MtDNA LHON mutations shows no synergistic effect on mitochondrial activity A Cruz-Bermudez, RJ Vicente-Blanco, R Hernandez-Sierra, M Montero, ... PLoS One 11 (1), e0146816, 2016 | 32 | 2016 |
| PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy A Cruz-Bermúdez, RJ Vicente-Blanco, R Laza-Briviesca, ... Scientific Reports 7 (1), 16661, 2017 | 25 | 2017 |
| Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment M Provencio, M Torrente, V Calvo, L Gutiérrez, D Pérez-Callejo, ... Oncotarget 8 (36), 60291, 2017 | 24 | 2017 |
| Spotlight on the relevance of mtDNA in cancer A Cruz-Bermúdez, RJ Vicente-Blanco, E González-Vioque, M Provencio, ... Clinical and Translational Oncology 19, 409-418, 2017 | 24 | 2017 |
| Atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer with high tumor mutation burden: a nonrandomized … M Provencio, AL Ortega, J Coves-Sarto, V Calvo, R Marsé-Fabregat, ... JAMA oncology 9 (3), 344-353, 2023 | 23 | 2023 |
| ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib A Romero, R Serna-Blasco, C Alfaro, E Sánchez-Herrero, M Barquín, ... Translational Lung Cancer Research 9 (3), 532, 2020 | 19 | 2020 |
| Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients M Provencio, D Pérez-Callejo, M Torrente, P Martin, V Calvo, L Gutiérrez, ... Oncotarget 8 (35), 59408, 2017 | 19 | 2017 |
| Evaluation of mitochondrial function and metabolic reprogramming during tumor progression in a cell model of skin carcinogenesis CG Vallejo, A Cruz-Bermúdez, P Clemente, R Hernández-Sierra, ... Biochimie 95 (6), 1171-1176, 2013 | 19 | 2013 |
